Hellenic Evaluation of the Long-Term Safety and Efficacy of NalIriFOx as a 1st-line Therapy in Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)

NCT07723261 · clinicaltrials.gov ↗
RECRUITING
Status
70
Enrollment
OTHER
Sponsor class

Conditions

Sponsor

Hellenic Cooperative Oncology Group